meta_pixel
Tapesearch Logo
Log in
What Next | Daily News and Analysis

A Vaccine Won’t Be the End

What Next | Daily News and Analysis

Slate Podcasts

News, News Commentary, Daily News

4.32.4K Ratings

🗓️ 25 September 2020

⏱️ 20 minutes

🧾️ Download transcript

Summary

As of Sept. 24, there are 42 vaccines in clinical trials on humans. At least 92 others are being developed but have not yet gone to trial. For months, the world has tracked the progression of these vaccines closely, with the expectation that once one arrives on the market, we can finally start to go back to normal. But, is that true? Does the world really look much different with an effective vaccine?


Guest: Dr. Paul Offit, professor of pediatrics at the Children's Hospital of Philadelphia.


Host

Celeste Headlee

 


Hosted on Acast. See acast.com/privacy for more information.

Transcript

Click on a timestamp to play from that location

0:00.0

Since the genetic sequence for the coronavirus was first made public in January,

0:09.0

scientists worldwide have been working on developing a vaccine.

0:13.0

Never before in history has it taken less than several years for a new vaccine to be produced.

0:19.0

Dr. Anthony Fauci says a COVID inoculation could be available to the public as soon as next January.

0:24.6

And this emphasis on speed has some people worried that politicians are pressuring scientists to cut corners.

0:32.1

But other people just want to know how soon they can get in line.

0:36.2

So where do you stand? People are being asked,

0:39.6

would you get a COVID-19 vaccine or said another way, would you get a theoretical COVID-19 vaccine

0:45.0

because there is no COVID-19 vaccine? That's Dr. Paul Offutt. Offutt is the director of the vaccine

0:50.8

education center at Children's Hospital of Philadelphia. He was also co-inventor of a

0:56.3

rotavirus vaccine and serves on the Vaccine Advisory Committee for the FDA. If you ask me that

1:02.4

question, if you said, would I get a COVID-19 vaccine? My answer to that would be not until I see the

1:07.8

data. Let me see whether or not my group is represented there,

1:11.9

whatever it is, whether it's African American or Latinx or obese or a health care worker or

1:17.4

someone over 65. You want to see that your group is represented in the safety data and the

1:22.3

efficacy data. But Paul says that data may not come for months. And when it does start to trickle in, don't expect certainty.

1:31.3

Instead, assume that you'll have to make educated guesses.

1:35.7

The question when you launch a medical product is not, do I know everything?

1:39.2

The question is, do you know enough to say that the benefits of this particular product outweigh its theoretical risks? I mean, do you know enough to say that the benefits of this particular product, that way it's theoretical

1:44.7

risks.

1:45.3

I mean, do you know enough to say that?

1:48.1

Sometimes there's unpleasant surprises, but that's the nature of medical breakthroughs.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Slate Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Slate Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.